Humoral and Cellular Immunogenicity to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Longitudinal Cohort Study
A research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity.
Tuesday, January 25, 2022
